moxifloxacin has been researched along with Intraabdominal Infections in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Criollo, M; DiCasoli, C; Digtyar, V; Emil, SGS; Engelis, A; Grossmann, U; Nkulikiyinka, R; Stass, H; Willmann, S; Wirth, S | 1 |
| Chen, CW; Ma, CJ; Ming, CC; Shan, YS; Wang, JY; Yeh, YS | 1 |
| Dwivedi, P; Gupta, PK; Mishra, PR; Rath, SK; Shukla, P; Verma, AK; Yadav, A | 1 |
| Alder, JD; Citron, DM; Goldstein, EJ; Solomkin, JS | 1 |
| Chen, CW; Chen, YH; Hsueh, PR; Huang, CT; Ko, WC; Lau, YJ; Lee, WS; Lee, YJ; Liu, CY; Liu, HD; Liu, JW | 1 |
| Deng, X; Liu, RL; Mu, YP; Wang, LQ; Wang, Y; Wei, MD; Zhu, N | 1 |
| Alder, J; Arvis, P; De Waele, JJ; Hampel, B; Jensen, M; Reimnitz, P; Tellado, JM | 1 |
2 review(s) available for moxifloxacin and Intraabdominal Infections
| Article | Year |
|---|---|
Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
Topics: Anti-Bacterial Agents; Asia; Aza Compounds; Community-Acquired Infections; Enterobacteriaceae Infections; Fluoroquinolones; Guidelines as Topic; Humans; Intraabdominal Infections; Moxifloxacin; Quinolines; Treatment Outcome | 2012 |
Moxifloxacin monotherapy for treatment of complicated intra-abdominal infections: a meta-analysis of randomised controlled trials.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Bacterial Infections; Fluoroquinolones; Humans; Intraabdominal Infections; Middle Aged; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
3 trial(s) available for moxifloxacin and Intraabdominal Infections
| Article | Year |
|---|---|
Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study.
Topics: Administration, Intravenous; Adolescent; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Child; Child, Preschool; Double-Blind Method; Female; Humans; Infant; Intraabdominal Infections; Male; Moxifloxacin; Prospective Studies | 2018 |
Prospective, randomized, study of ampicillin-sulbactam versus moxifloxacin monotherapy for the treatment of community-acquired complicated intra-abdominal infections.
Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Analysis of Variance; Anti-Bacterial Agents; Aza Compounds; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Intraabdominal Infections; Logistic Models; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Risk Factors; Sulbactam; Taiwan; Treatment Outcome; Young Adult | 2013 |
Randomised clinical trial of moxifloxacin versus ertapenem in complicated intra-abdominal infections: results of the PROMISE study.
Topics: Administration, Intravenous; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Fluoroquinolones; Humans; Incidence; Intraabdominal Infections; Male; Middle Aged; Moxifloxacin; Prospective Studies; Quinolines; Treatment Outcome | 2013 |
2 other study(ies) available for moxifloxacin and Intraabdominal Infections
| Article | Year |
|---|---|
Moxifloxacin-loaded nanoemulsions having tocopheryl succinate as the integral component improves pharmacokinetics and enhances survival in E. coli-induced complicated intra-abdominal infection.
Topics: Animals; Escherichia coli; Fluoroquinolones; Interleukin-6; Intraabdominal Infections; Male; Moxifloxacin; Rats; Sepsis; Tumor Necrosis Factor-alpha | 2014 |
Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria, Anaerobic; Bacteroides Infections; Clostridium Infections; Fluoroquinolones; Humans; Intraabdominal Infections; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |